Pay in installments of $31.25 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Promo Codes Available:
For Your Every Summer RSVP, with Code: SUMMER15
Description
CD19 His Tag Protein, Cynomolgus/Rhesus macaqueProduct Specification Species Cynomolgus, Rhesus macaque Synonyms B4,CVID3,MGC12802 Accession F7F486 1 Amino Acid Sequence Pro20 Lys292 with His Tag at the C Terminus Expression System HEK293 Molecular Weight 40 55kDa (Reducing) Purity 90% by SDS PAGE Conjugation Unconjugated Tag His Tag Physical Appearance Lyophilized powder Storage Buffer PBS, PH7. 4, 5% trehalose Reconstitution Reconstitute at 0. 1 1 mg ml according to the size in ultrapure water
Product Specification
| Species | Cynomolgus, Rhesus macaque |
| Synonyms | B4,CVID3,MGC12802 |
| Accession | F7F486-1 |
| Amino Acid Sequence | Pro20-Lys292 with His Tag at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 40-55kDa (Reducing) |
| Purity | ＞90% by SDS-PAGE |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, PH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | 1.Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010 Oct;335(1):213-22. |
Background
CD19 (Cluster of Differentiation 19) is a 95 kDa type I transmembrane glycoprotein belonging to the immunoglobulin superfamily, encoded by the CD19 gene located on the short arm of chromosome 16 (16p11.2). It serves as a lineage-specific B cell marker, expressed continuously from the pro-B cell stage until its downregulation prior to terminal differentiation into plasma cells. Structurally, CD19 comprises two extracellular Ig-like domains (C2 type), a transmembrane region, and an intracellular domain containing multiple tyrosine residues that interact with Src family kinases (such as Lyn and Fyn) and the PI3K/AKT signaling pathway. Functioning as a co-receptor for the B cell receptor (BCR), CD19 lowers the threshold for B cell activation and enhances antigen responsiveness, playing essential roles in B cell development, proliferation, differentiation, and antibody production. Under pathological conditions, CD19 is highly expressed in the vast majority of B cell malignancies (including B-ALL, diffuse large B cell lymphoma, and follicular lymphoma), making it an ideal target for immunotherapy. Chimeric antigen receptor T cell (CAR-T) therapies (such as Tisagenlecleucel and Axicabtagene ciloleucel) and bispecific T cell engagers (such as Blinatumomab) developed based on this target have achieved breakthrough efficacy in hematologic malignancy treatment. Furthermore, CD19-targeted therapy has demonstrated potential in inducing B cell depletion and disease remission in autoimmune diseases such as systemic lupus erythematosus, though vigilance is required for adverse effects including cytokine release syndrome and neurotoxicity.
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy